紐約大學研究員獲美國國立衛生研究院撥款，優化CAR-T細胞癌治療!，相信這個問題是許多正在準備留學的同學關心的一個問題，那么下面小編就來和大家說一說，感興趣的您趕緊往下了解吧。

　　紐約大學研究員獲美國國立衛生研究院（National Institutes of Health）撥款，優化CAR-T細胞癌治療

　　BROOKLYN, New York, Monday, October 28, 2019 –Weiqiang Chen, assistant professor of biomedical engineering and mechanical and aerospace engineering at the NYU Tandon School of Engineering, has been awarded the Maximizing Investigators’ Research Award (R35) from the National Institute of General Medical Sciences, a pision of the National Institutes of Health (NIH). The five-year, $1.7 million grant will support Chen’s lab’s efforts to devise engineering-based methods for understanding and improving the efficacy of immunotherapy treatment for cancer. 

　　2019年10月28日，星期一，紐約布魯克林區——紐約大學TANDUN工程學院生物醫學工程和機械與航空工程助理教授Weiqiang Chen被授予國立醫學研究所最大的研究者研究獎（R35），美國國立衛生研究院的一個部門。這項為期5年、170萬美元的撥款將支持陳的實驗室努力設計基于工程的方法，以了解和提高癌癥免疫治療的療效。

　　Chen, who heads NYU Tandon’s Applied Micro-Bioengineering Laboratory, explained that the grant will advance three key areas of interdisciplinary research aimed at developing personalized approaches to CAR-T cell therapy, a rapidly advancing cancer treatment modality that can produce remarkable results in select patients, yet carries significant risks. 

　　紐約大學坦頓應用微生物工程實驗室的負責人陳解釋說，這項撥款將推進跨學科研究的三個關鍵領域，旨在開發個性化的car-t細胞治療方法，這是一種快速發展的癌癥治療方法，可以在選定的患者身上產生顯著的效果，但也具有重要風險。

　　The funds will support the continued development of Chen’s microfluidic “organ on a chip” systems to model disease environments and study cell interactions. This approach, which uses cells from inpidual cancer patients to create personalized, in-vitro disease models, can quickly provide key information about the potential efficacy of treatment methods—including CAR-T—against a patient’s own cancer. “Once you try a cancer therapy, it can take six months to know if it’s working,” said Chen. “By studying the interactions between tumor cells and T-cells in-vitro, we can determine if a patient is likely to be responsive in just two weeks, and our system allows us to test 10 or more treatments in parallel to find the best option.” 

　　這些資金將支持陳的微流控“芯片上的器官”系統的持續發展，以模擬疾病環境和研究細胞間的相互作用這種方法利用單個癌癥患者的細胞創建個性化的體外疾病模型，可以快速提供關于治療方法（包括CAR-T）對患者自身癌癥的潛在療效的關鍵信息“一旦你嘗試癌癥治療，可能需要6個月才能知道它是否有效，”陳說“通過在體外研究腫瘤細胞和T細胞之間的相互作用，我們可以確定患者是否可能在兩周內產生反應，我們的系統允許我們同時測試10種或更多的治療方法，以找到最佳選擇。” 

　　Leukemia-on-a-Chip cancer microenvironment uses cells from inpidual cancer patients to create personalized, in-vitro disease models, which can quickly provide key information about the potential efficacy of treatment methods. 

　　白血病芯片上的癌癥微環境利用單個癌癥患者的細胞創建個性化的體外疾病模型，可以快速提供有關治療方法潛在療效的關鍵信息。

　　Chen’s research, which blends engineering and medicine, is also probing the mechanical forces at play during interactions between immune cells and cancer cells, particularly during the process by which the former kills the later. Additionally, in a study published recently in the journal Advanced Materials, Chen described a novel mechanical system for measuring how local stress on a cell causes physical changes that could flag chronic diseases. He noted that there are force-mediated changes in T-cell morphology that facilitate their attachment to cancer cells, and additional forces applied as immune cells eradicate tumor cells. Through this novel investigation into the mechanobiology of CAR-T cells, Chen and his collaborators hope to illuminate, and eventually optimize, the cell mechanics involved in these interactions. 

　　陳的研究將工程學和醫學結合在一起，同時也在探索免疫細胞和癌細胞之間的相互作用過程中，特別是前者殺死后者的過程中所發揮的機械力。此外，在最近發表在《先進材料》雜志上的一項研究中，陳描述了一種新的機械系統，用于測量細胞局部應力如何導致可能標志慢性疾病的物理變化。他指出，在T細胞形態上有力介導的改變，有助于它們附著在癌細胞上，而在免疫細胞消滅腫瘤細胞時也有額外的力通過對CAR-T細胞機制生物學的新研究，陳和他的合作者希望闡明并最終優化參與這些相互作用的細胞機制。

　　Finally, the grant will advance a longstanding area of Chen’s work—the development of biosensors capable of measuring chemical communication between cells. In this case, Chen aims to create sensors to detect and measure the biochemicals that facilitate communication between immune cells and tumor cells during CAR-T cell therapy. 

　　最后，這項撥款將推動陳的一項長期工作，即開發能夠測量細胞間化學通訊的生物傳感器在這種情況下，陳的目標是創建傳感器來檢測和測量在car-t細胞治療期間促進免疫細胞和腫瘤細胞之間通信的生化物質。

　　The R35 is Chen’s second award from the National Institutes of Health. Last year Chen received the National Institute of Biomedical Imaging and Bioengineering Trailblazer R21 Award for a lab-on-a-chip system for testing immunotherapy for glioblastoma, “Engineered Glioblastoma Tumor Immunity for Personalized Immunotherapy.” 

　　R35是陳在國立衛生研究院獲得的第二個獎項。去年，陳獲得了國家生物醫學成像與生物工程研究所（National Institute of Biomedical Imaging and BioEngineering Trailzer R21）頒發的膠質母細胞瘤免疫檢測芯片系統“工程化膠質母細胞瘤腫瘤免疫個性化免疫治療”獎。

　　Earlier this month, he was one of just 12 researchers to be named a 2019 Young Innovator by the Biomedical Engineering Society. 

關于紐約大學研究員獲美國國立衛生研究院撥款，優化CAR-T細胞癌治療!這個問題本文的分享就到這里結束了，如果您還想了解更多相關的內容，那么可以持續關注本頻道。

>>免費領全球留學白皮書，了解各大學報考條件、費用、開學時間、含金量<<